|
VX15/2503 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Anti-SEMA4D Monoclonal Antibody VX15/2503, Pepinemab, moAb VX15/2503
Atlanta, Georgia1 trial
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Emory University Hospital Midtown
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.